Top Ten most popular articles on Pharmafile.com this week
Another week has whizzed round again as we race into Spring, and a breadth of stories have piqued the interests of our readers over the past week. A new partnership between Allergan and Novartis to tackle non-alchoholic steatohepatitis was big news, as was Pfizer's new pledge to assist new start-up companies in the industry. But the topic which proved most popular has been trial failures, with both AbbVie and Circassia releasing disappointing results on their products.
Check out the week's ten most popular articles on Pharmafile.com now!
Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded indication in the US after approval by the FDA for advanced bladder cancer.
A new study has suggested that cannabidiol, a molecule derived from cannabis without its psychoactive effects, can prove beneficial for some sufferers of Lennox-Gastaut syndrome (LGS) in reducing seizures by up to 50%.
Why is it that people are still prepared to trust the internet when it comes to their health? Ben Hargreaves examines the rise of fake medicines and the different ways in which the pharmaceutical and healthcare industries are fighting back.
St Jude Medical has been hit with a warning letter from the FDA over the medical device manufacturer’s failure to address issues with its implantable defibrillators and at-home monitoring equipment.
Allergan and Novartis have announced a new partnership to conduct a clinical trial in the treatment area of non-alcoholic steatohepatitis (NASH), evaluating two of their treatments as a combination therapy.
A team of scientists have identified methods to prevent neurodegeneration in mice, leading to new hopes in the treatment of diseases such as Alzheimer’s and Parkinson’s in humans.
The implementation of a new regulation is on the horizon which could be revolutionary for the future of clinical trials across Europe. However, recent world events could cause considerable disruption to this progress, as Matt Fellows discovers.
Pfizer has announced the launch of ‘Pfizer Healthcare Hub: London’, a project that aims to help startups, focusing on the development of technology in healthcare, to grow to ‘reach more patients and providers’.
AbbVie have released that two Phase 3 trials of its experimental cancer drug, veliparib, missed both of their primary endpoints.
Circassia has slumped at the Phase 2 clinical trial stage again, as its treatment for dust mite allergies was unable to improve on placebo treatment.